Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9C019
UPID:
TRI15_HUMAN
Alternative names:
RING finger protein 93; Zinc finger protein 178; Zinc finger protein B7
Alternative UPACC:
Q9C019; A2BEC9; O95604; Q8IUX9; Q9C018
Background:
E3 ubiquitin-protein ligase TRIM15, also known as RING finger protein 93, plays a pivotal role in innate antiviral immunity, cell migration, and chemotaxis. It functions as a 'Lys-63'-specific ubiquitin ligase for MAPK1/ERK2 and MAPK3/ERK1, enhancing their activation. TRIM15 is a key player in the RIGI-mediated interferon induction pathway and regulates the activation of hepatic stellate cells (HSCs), highlighting its multifaceted role in biological systems.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase TRIM15 could open doors to potential therapeutic strategies.